Influenza antivirals and their role in pandemic preparedness

JC Jones, HL Yen, P Adams, K Armstrong… - Antiviral Research, 2023‏ - Elsevier
Effective antivirals provide crucial benefits during the early phase of an influenza pandemic,
when vaccines are still being developed and manufactured. Currently, two classes of viral …

[HTML][HTML] Recent advances in molecular mechanisms of nucleoside antivirals

PN Kamzeeva, AV Aralov, VA Alferova… - Current Issues in …, 2023‏ - mdpi.com
The search for new drugs has been greatly accelerated by the emergence of new viruses
and drug-resistant strains of known pathogens. Nucleoside analogues (NAs) are a …

Favipiravir treatment of uncomplicated influenza in adults: results of two phase 3, randomized, double-blind, placebo-controlled trials

FG Hayden, RP Lenk, L Stonis… - The Journal of …, 2022‏ - academic.oup.com
Background We conducted double-blind, placebo-controlled trials assessing the efficacy
and tolerability of favipiravir in acute influenza. Methods Otherwise healthy adults with …

Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences

K Shiraki, N Sato, K Sakai, S Matsumoto… - Pharmacology & …, 2022‏ - Elsevier
Favipiravir, a broad-spectrum RNA-dependent RNA polymerase inhibitor, inhibits the
replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at …

Lethal mutagenesis of RNA viruses and approved drugs with antiviral mutagenic activity

I Hadj Hassine, M Ben M'hadheb, L Menéndez-Arias - Viruses, 2022‏ - mdpi.com
In RNA viruses, a small increase in their mutation rates can be sufficient to exceed their
threshold of viability. Lethal mutagenesis is a therapeutic strategy based on the use of …

A review on favipiravir: the properties, function, and usefulness to treat COVID-19

SMR Hashemian, T Farhadi… - Expert review of anti …, 2021‏ - Taylor & Francis
Introduction At this time, there is no specific therapeutic or vaccine for treatment of the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hence, available drugs for …

Influenza antivirals and animal models

CJ Caceres, B Seibert, F Cargnin Faccin… - FEBS Open …, 2022‏ - Wiley Online Library
Influenza A and B viruses are among the most prominent human respiratory pathogens.
About 3–5 million severe cases of influenza are associated with 300 000–650 000 deaths …

Lethal mutagenesis of RNA viruses and approved drugs with antiviral mutagenic activity

IH Hassine, MB M'hadheb, L Menéndez-Arias - Viruses, 2022‏ - pmc.ncbi.nlm.nih.gov
In RNA viruses, a small increase in their mutation rates can be sufficient to exceed their
threshold of viability. Lethal mutagenesis is a therapeutic strategy based on the use of …

Influenza polymerase inhibitor resistance: Assessment of the current state of the art-A report of the isirv Antiviral group

MG Ison, FG Hayden, AJ Hay, LV Gubareva… - Antiviral research, 2021‏ - Elsevier
It is more than 20 years since the neuraminidase inhibitors, oseltamivir and zanamivir were
approved for the treatment and prevention of influenza. Guidelines for global surveillance …

[HTML][HTML] Favipiravir induces HuNoV viral mutagenesis and infectivity loss with clinical improvement in immunocompromised patients

AY Kreins, E Roux, J Pang, I Cheng, O Charles… - Clinical …, 2024‏ - Elsevier
Chronic human norovirus (HuNoV) infections in immunocompromised patients result in
severe disease, yet approved antivirals are lacking. RNA-dependent RNA polymerase …